Pfizer – Approaches to Increase Equitable Access to and Delivery of Quality of Care with Bispecific Antibodies for Patients with Multiple Myeloma Request for Proposals (RFP)
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire within unit
Memorial Deadline: Friday 26th, May 2023
External Deadline: Thursday 1st, June 2023
Description
| The International Myeloma Foundation (IMF) and Pfizer are pleased to collaborate to offer a grant opportunity to support Quality Improvement (QI) projects that will advance the quality of care and best practices around treatment for patients with relapse/refractory multiple myeloma (RRMM) receiving treatment with a bispecific antibody (BsAb).
The International Myeloma Foundation (IMF) is the first and largest global organization focusing specifically on multiple myeloma. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program. |
| Date RFP Issued: March 31, 2023
Geographic Scope: Global Clinical Area: Relapsed/Refractory Multiple Myeloma Link to full RFP: Approaches to Increase Equitable Access to and Delivery of Quality of Care with Bispecific Antibodies for Patients with Multiple Myeloma Application Due Date: June 1, 2023 Specific Area of Interest: The intent of this Request for Proposal (RFP) is to support Quality Improvement initiatives that will increase equitable access to and delivery of quality care for patients with multiple myeloma in the community. |
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Haleigh Wolfe (hwolfe@myeloma.org) for IMF related questions or Pfizer’s Grant Officer, Amanda Kaczerski (Amanda.Kaczerski@pfizer.com).